FDA Approved Indications for this Orphan Drug:

Treatment of adults with metastatic melanoma.

FDA Marketing Approval issued as of:
01/09/1998

Orphan Drug exclusivity ends on:
01/09/2005
Company Making and Marketing this drug:
Chiron Corporation

FDA Designation Date:
9/10/96

FDA Drug Designation:
Treatment of metastatic melanoma.